Clinical Trials Logo

Filter by:
NCT ID: NCT03337763 Completed - Heart Failure Clinical Trials

A Prospective Pilot Study (BIO|SELECT Pilot)

Start date: November 7, 2017
Phase:
Study type: Observational [Patient Registry]

Enrolled patients implanted with Biotronik CRT-D and QP lead equipped with MultiPole pacing mode is grouped into which programmed into MultiPole pacing, or conventional bi-ventricular pacing mode. They are followed up by seven month post implantation, and predefined cardiac functional parameters are collected at each visit.

NCT ID: NCT03337724 Completed - Breast Cancer Clinical Trials

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

IPATunity130
Start date: January 6, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.

NCT ID: NCT03336645 Completed - Clinical trials for Nervous System Diseases

Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan

Start date: October 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.

NCT ID: NCT03336450 Completed - Clinical trials for Nervous System Diseases

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

Start date: April 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting. This study is open-label extension for patients who completed the SHP615-301 study and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.

NCT ID: NCT03336216 Completed - Clinical trials for Advanced Pancreatic Cancer

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

NCT ID: NCT03335852 Completed - Clinical trials for Macular Degeneration

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

PINE
Start date: November 28, 2017
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and to characterize the systemic pharmacokinetics of free and vascular endothelial growth factor (VEGF)-bound abicipar following multiple monthly intravitreal injections of abicipar in Japanese patients with neovascular age-related macular degeneration (AMD).

NCT ID: NCT03334435 Completed - Atopic Dermatitis Clinical Trials

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

BREEZE-AD3
Start date: March 28, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis. Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.

NCT ID: NCT03334422 Completed - Atopic Dermatitis Clinical Trials

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

BREEZE-AD2
Start date: November 27, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.

NCT ID: NCT03334396 Completed - Atopic Dermatitis Clinical Trials

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

BREEZE-AD1
Start date: November 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.

NCT ID: NCT03333317 Terminated - Clinical trials for Respiratory Syncytial Viruses

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Start date: November 24, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal RSV shedding using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).